Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy - a randomized trial

被引:107
作者
El-Sadr, W. M.
Grund, B.
Neuhaus, J.
Babiker, A.
Cohen, C. J.
Darbyshire, J.
Emery, S.
Lundgren, J. D.
Phillips, A.
Neaton, J. D.
机构
[1] Columbia Univ, Harlem Hosp Ctr, New York, NY USA
[2] Community Res Initiat New England, Boston, MA USA
[3] MRC, Clin Trials Unit, London, England
[4] Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia
[5] Univ Copenhagen, Copenhagen, Denmark
[6] Rigshosp, DK-2100 Copenhagen, Denmark
基金
美国国家卫生研究院; 英国医学研究理事会;
关键词
D O I
10.7326/0003-4819-149-5-200809020-00003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Episodic use of antiretroviral therapy guided by CD4(+) cell counts is inferior to continuous antiretroviral therapy. Objective: To determine whether reinitiating continuous antiretroviral therapy in patients who received episodic treatment reduces excess risk for opportunistic disease or death. Design: Randomized, controlled trial. Patients: 5472 HIV-infected individuals with CD4(+) cell counts greater than 0.350 x 10(9) cells/L enrolled from January 2002 to January 2006. Intervention: Episodic or continuous antiretroviral therapy initially, followed by continuous therapy in participants previously assigned to episodic treatment. Results: Eighteen months after the recommendation to reinitiate continuous therapy, mean CD4(+) cell counts were 0.152 x 10(9) cells/L (95% CI, 0.136 to 0.167 x 10(9) cells/ L) less in participants previously assigned to episodic treatment (P < 0.001). The proportion of follow-up time spent with CD4(+) cell counts of 0.500 x 10(9) cells/L or more and HIV RNA levels of 400 copies/mL or less was 29% for participants initially assigned to episodic therapy and 66% for those assigned to continuous therapy. Participants who reinitiated continuous therapy experienced rapid suppression of HIV RNA levels (89.7% with HIV RNA levels <= 400 copies/mL after 6 months), but CD4(+) cell counts after 6 months remained 0.140 x 10(9) cells/L below baseline. The hazard ratio (episodic versus continuous treatment) for opportunistic disease or death decreased after the recommendation to reinitiate continuous therapy (from 2.5 [CI, 1.8 to 3.5] to 1.4 [CI, 1.0 to 2.0]; P = 0.033 for difference). The residual excess risk was attributable to failure to reinitiate therapy by some participants and slow recovery of CD4(+) cell counts for those who reinitiated therapy. Limitation: Follow-up was too short to assess the full effect of switching from episodic to continuous antiretroviral therapy. Conclusion: Reinitiating continuous antiretroviral therapy in patients previously assigned to episodic treatment reduced excess risk for opportunistic disease or death, but excess risk remained. Episodic antiretroviral therapy, as used in the SMART study, should be avoided.
引用
收藏
页码:289 / W62
页数:14
相关论文
共 22 条
[1]  
Ananworanich J, 2005, JAIDS-J ACQ IMM DEF, V39, P523
[2]   CD4+count and risk of non-AIDS diseases following initial treatment for HIV infection [J].
Baker, Jason V. ;
Peng, Grace ;
Rapkin, Joshua ;
Abrams, Donald I. ;
Silverberg, Michael J. ;
MacArthur, Rodger D. ;
Cavert, Winston P. ;
Henry, W. Keith ;
Neaton, James D. .
AIDS, 2008, 22 (07) :841-848
[3]  
Beral V, 2004, AIDS, V18, P51, DOI [10.1097/01.aids.0000096908.73209.5d, 10.1097/00002030-200401020-00006]
[4]  
Bogaards JA, 2003, ANTIVIR THER, V8, P43
[5]   Safety and factors predicting the duration of first and second treatment interruptions guided by CD4+cell counts in patients with chronic HIV infection [J].
Boschi, A ;
Tinelli, C ;
Ortolani, P ;
Arlotti, M .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 57 (03) :520-526
[6]   The impact of episodic CD4 cell count-guided antiretroviral therapy on quality of life [J].
Burman, William J. ;
Grund, Birgit ;
Roedige, Mollie P. ;
Friedland, Gerald ;
Darhyshire, Janet ;
Wu, Albert W. .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2008, 47 (02) :185-193
[7]   Immunologic and virologic consequences of temporary antiretroviral treatment interruption in clinical practice [J].
Chen, RY ;
Westfall, AO ;
Raper, JL ;
Cloud, GA ;
Chatham, AK ;
Acosta, EP ;
Pham, SV ;
Tolson, JM ;
Heudebert, GR ;
Saag, MS .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2002, 18 (13) :909-916
[8]  
El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283, DOI 10.1056/NEJMoa062360
[9]   Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study [J].
Emery, Sean ;
Neuhaus, Jacqueline A. ;
Phillips, Andrew N. ;
Babiker, Abdel ;
Cohen, Calvin J. ;
Gatell, Jose M. ;
Girard, Pierre-Marie ;
Grund, Birgit ;
Law, Matthew ;
Losso, Marcelo H. ;
Palfreeman, Adrian ;
Wood, Robin .
JOURNAL OF INFECTIOUS DISEASES, 2008, 197 (08) :1133-1144
[10]   CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater [J].
Gras, Luuk ;
Kesselring, Anouk M. ;
Griffin, James T. ;
van Sighem, Ard I. ;
Fraser, Christophe ;
Ghani, Azra C. ;
Miedema, Frank ;
Reiss, Peter ;
Lange, Joep M. A. ;
de Wolf, Frank .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2007, 45 (02) :183-192